IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Every FINRA and SEC series the site collects for IOVANCE BIOTHERAPEUTICS, INC.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
102.9M
Short interest
settlement 2026-08-14
4.8
Days to cover
+3.0% vs prior
42.5%
Short share of volume
2026-09-11
4,096
Fails to deliver
settlement 2026-08-11
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in IOVA is 102,940,590 shares, up 3,047,652 shares over the last month. Over the last 48 readings it ranged from 53,988,814 shares (15 November 2024) to 131,334,639 shares (13 February 2026). At the reported average volume of 21.5M shares a day that is 4.8 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/iova" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 102,940,590 | +3.0% | 21,509,752 | 4.79 |
| 2026-07-31 | 99,975,709 | +0.1% | 15,923,753 | 6.28 |
| 2026-07-15 | 99,892,938 | -0.6% | 16,903,817 | 5.91 |
| 2026-06-30 | 100,526,623 | -2.9% | 14,159,736 | 7.10 |
| 2026-06-15 | 103,489,642 | -0.7% | 13,107,577 | 7.90 |
| 2026-05-29 | 104,249,751 | -2.2% | 12,722,798 | 8.19 |
| 2026-05-15 | 106,608,353 | -7.1% | 17,782,438 | 6.00 |
| 2026-04-30 | 114,711,667 | +5.4% | 12,535,651 | 9.15 |
| 2026-04-15 | 108,804,045 | -1.8% | 16,639,967 | 6.54 |
| 2026-03-31 | 110,832,243 | -3.7% | 11,697,703 | 9.47 |
| 2026-03-13 | 115,070,206 | -12.1% | 23,097,517 | 4.98 |
| 2026-02-27 | 130,927,595 | -0.3% | 18,040,821 | 7.26 |
| 2026-02-13 | 131,334,639 | +24.8% | 8,986,769 | 14.61 |
| 2026-01-30 | 105,255,004 | -10.1% | 13,899,672 | 7.57 |
| 2026-01-15 | 117,099,153 | -1.7% | 11,562,081 | 10.13 |
| 2025-12-31 | 119,070,866 | -1.1% | 13,446,524 | 8.86 |
| 2025-12-15 | 120,342,810 | +1.2% | 9,501,925 | 12.67 |
| 2025-11-28 | 118,939,462 | +2.8% | 10,055,957 | 11.83 |
| 2025-11-14 | 115,733,068 | +21.3% | 28,665,756 | 4.04 |
| 2025-10-31 | 95,415,882 | +14.1% | 12,863,511 | 7.42 |
| 2025-10-15 | 83,612,571 | +14.6% | 11,319,936 | 7.39 |
| 2025-09-30 | 72,971,971 | +11.1% | 10,139,600 | 7.20 |
| 2025-09-15 | 65,704,715 | -7.9% | 9,311,224 | 7.06 |
| 2025-08-29 | 71,319,978 | -0.1% | 12,497,239 | 5.71 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of IOVA volume is 42.5%, down 7.0 points over the last five sessions. Over the last 52 readings it ranged from 29.4% (10 August 2026) to 63.5% (14 July 2026). The latest reading is 2.4 points above the 30-session average of 40.1%, on 6.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 2.6M | 6.1M | 42.5% | 41,346 |
| 2026-09-10 | 3.5M | 6.2M | 57.2% | 2,400 |
| 2026-09-09 | 3.3M | 6.6M | 49.0% | 2,846 |
| 2026-09-08 | 2.0M | 4.6M | 43.7% | 7,086 |
| 2026-09-04 | 2.1M | 4.3M | 48.1% | 1,574 |
| 2026-09-03 | 2.4M | 4.9M | 49.4% | 4,965 |
| 2026-09-02 | 2.5M | 6.0M | 42.2% | 34,713 |
| 2026-09-01 | 1.3M | 3.2M | 40.9% | 1,872 |
| 2026-08-31 | 1.8M | 5.3M | 33.5% | 9,430 |
| 2026-08-28 | 1.7M | 4.1M | 40.7% | 4,294 |
| 2026-08-27 | 1.5M | 4.1M | 36.3% | 2,411 |
| 2026-08-26 | 2.4M | 5.0M | 47.6% | 2,512 |
| 2026-08-25 | 1.8M | 5.1M | 34.4% | 25,359 |
| 2026-08-24 | 2.6M | 7.7M | 34.4% | 19,324 |
| 2026-08-21 | 4.2M | 13.6M | 30.9% | 91,025 |
| 2026-08-20 | 9.3M | 19.8M | 46.8% | 43,379 |
| 2026-08-19 | 3.8M | 11.7M | 32.4% | 79,534 |
| 2026-08-18 | 2.6M | 5.8M | 44.3% | 65,065 |
| 2026-08-17 | 3.1M | 7.7M | 40.3% | 18,245 |
| 2026-08-14 | 4.0M | 9.5M | 41.8% | 18,995 |
| 2026-08-13 | 3.8M | 9.2M | 41.1% | 27,516 |
| 2026-08-12 | 1.7M | 5.7M | 29.5% | 8,612 |
| 2026-08-11 | 1.8M | 5.4M | 32.6% | 9,578 |
| 2026-08-10 | 2.6M | 8.7M | 29.4% | 58,295 |
| 2026-08-07 | 5.1M | 16.7M | 30.4% | 30,820 |
| 2026-08-06 | 10.7M | 33.2M | 32.2% | 316,279 |
| 2026-08-05 | 3.9M | 7.5M | 51.8% | 15,142 |
| 2026-08-04 | 1.9M | 4.9M | 40.1% | 19,789 |
| 2026-08-03 | 2.4M | 6.0M | 40.7% | 235,881 |
| 2026-07-31 | 4.0M | 10.3M | 39.1% | 338,259 |
Fails to deliver
SEC, by settlement date. JSONAs of 11 August 2026, the fails-to-deliver balance in IOVA is 4,096 shares, down 9,090 shares over the last settlement date. Over the last 52 readings it ranged from 247 shares (8 April 2026) to 951,749 shares (12 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-11 | 4,096 | $6.40 | $26K |
| 2026-08-07 | 13,186 | $6.21 | $82K |
| 2026-08-04 | 154,353 | $4.32 | $667K |
| 2026-08-03 | 236,695 | $4.07 | $963K |
| 2026-07-24 | 39,206 | $5.13 | $201K |
| 2026-07-23 | 27,065 | $5.17 | $140K |
| 2026-07-22 | 33,525 | $5.48 | $184K |
| 2026-07-20 | 23,227 | $5.00 | $116K |
| 2026-07-17 | 256,612 | $4.66 | $1.2M |
| 2026-07-14 | 918 | $4.04 | $4K |
| 2026-07-08 | 265 | $4.35 | $1K |
| 2026-07-06 | 29,299 | $4.31 | $126K |
| 2026-06-29 | 380,213 | $4.25 | $1.6M |
| 2026-06-26 | 5,137 | $4.21 | $22K |
| 2026-06-23 | 273,784 | $4.06 | $1.1M |
| 2026-06-22 | 340,285 | $3.91 | $1.3M |
| 2026-06-15 | 59,445 | $4.08 | $243K |
| 2026-06-12 | 1,597 | $3.96 | $6K |
| 2026-06-09 | 2,894 | $4.00 | $12K |
| 2026-06-08 | 1,244 | $4.23 | $5K |
| 2026-06-05 | 811,799 | $4.38 | $3.6M |
| 2026-06-03 | 2,526 | $4.10 | $10K |
| 2026-06-02 | 923,145 | $3.96 | $3.7M |
| 2026-04-30 | 3,327 | $3.31 | $11K |
| 2026-04-16 | 54,439 | $3.82 | $208K |
| 2026-04-10 | 1,397 | $4.01 | $6K |
| 2026-04-08 | 247 | $3.32 | $820 |
| 2026-04-02 | 11,740 | $3.45 | $41K |
| 2026-04-01 | 27,047 | $3.51 | $95K |
| 2026-03-31 | 462 | $3.32 | $2K |
Insider trades
SEC Form 4, newest first, 50 of 72 shown. JSONNo open-market insider trades were reported for IOVA in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: BILINSKY IGOR (Chief Operating Officer) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $8.70 | $35K | 142K |
| 2026-09-08 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 8K | $0.00 | $0 | 146K |
| 2026-09-01 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 18K | $8.28 | $147K | 586K |
| 2026-09-01 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 42K | $0.00 | $0 | 604K |
| 2026-09-01 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $8.28 | $21K | 251K |
| 2026-09-01 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 5K | $0.00 | $0 | 254K |
| 2026-09-01 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $8.28 | $37K | 138K |
| 2026-09-01 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 9K | $0.00 | $0 | 143K |
| 2026-08-10 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 2K | $6.40 | $16K | 155K |
| 2026-08-10 | Kirby Daniel Gordon | Chief Commercial Officer | Option exercise | 10K | $0.00 | $0 | 157K |
| 2026-08-06 | Roche Corleen M. | Chief Financial Officer | Tax withholding | 21K | $6.21 | $132K | 29K |
| 2026-08-06 | Roche Corleen M. | Chief Financial Officer | Option exercise | 50K | $0.00 | $0 | 50K |
| 2026-06-05 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 7K | $4.23 | $28K | 562K |
| 2026-06-05 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 16K | $0.00 | $0 | 569K |
| 2026-06-05 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 4K | $4.23 | $16K | 248K |
| 2026-06-05 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 10K | $0.00 | $0 | 252K |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 4K | $4.23 | $17K | 140K |
| 2026-06-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Option exercise | 8K | $0.00 | $0 | 144K |
| 2026-06-05 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $4.23 | $17K | 134K |
| 2026-06-05 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 8K | $0.00 | $0 | 138K |
| 2026-06-01 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 18K | $3.96 | $70K | 554K |
| 2026-06-01 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 42K | $0.00 | $0 | 571K |
| 2026-06-01 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $3.96 | $10K | 242K |
| 2026-06-01 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 5K | $0.00 | $0 | 245K |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 4K | $3.96 | $18K | 136K |
| 2026-06-01 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Option exercise | 9K | $0.00 | $0 | 141K |
| 2026-06-01 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 4K | $3.96 | $18K | 130K |
| 2026-06-01 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 9K | $0.00 | $0 | 135K |
| 2026-05-11 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 2K | $3.70 | $9K | 147K |
| 2026-05-11 | Kirby Daniel Gordon | Chief Commercial Officer | Option exercise | 10K | $0.00 | $0 | 149K |
| 2026-03-05 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 27K | $4.58 | $123K | 530K |
| 2026-03-05 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 62K | $0.00 | $0 | 556K |
| 2026-03-05 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 18K | $4.58 | $84K | 239K |
| 2026-03-05 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 39K | $0.00 | $0 | 258K |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 17K | $4.58 | $76K | 132K |
| 2026-03-05 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Option exercise | 31K | $0.00 | $0 | 148K |
| 2026-03-05 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 17K | $4.58 | $76K | 126K |
| 2026-03-05 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 31K | $0.00 | $0 | 142K |
| 2026-03-02 | Vogt Frederick G | Interim CEO & General Counsel | Tax withholding | 23K | $3.79 | $86K | 494K |
| 2026-03-02 | Vogt Frederick G | Interim CEO & General Counsel | Option exercise | 52K | $0.00 | $0 | 517K |
| 2026-03-02 | Puri Raj K. | Chief Regulatory Officer | Tax withholding | 3K | $3.79 | $11K | 219K |
| 2026-03-02 | Puri Raj K. | Chief Regulatory Officer | Option exercise | 5K | $0.00 | $0 | 221K |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Tax withholding | 7K | $3.79 | $27K | 117K |
| 2026-03-02 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | Option exercise | 13K | $0.00 | $0 | 124K |
| 2026-03-02 | BILINSKY IGOR | Chief Operating Officer | Tax withholding | 7K | $3.79 | $26K | 111K |
| 2026-03-02 | BILINSKY IGOR | Chief Operating Officer | Option exercise | 12K | $0.00 | $0 | 118K |
| 2026-02-24 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 34K | $3.78 | $129K | 139K |
| 2026-02-24 | Kirby Daniel Gordon | Chief Commercial Officer | Option exercise | 120K | $0.00 | $0 | 174K |
| 2026-02-10 | Kirby Daniel Gordon | Chief Commercial Officer | Tax withholding | 16K | $2.60 | $43K | 54K |
| 2026-02-10 | Kirby Daniel Gordon | Chief Commercial Officer | Option exercise | 40K | $0.00 | $0 | 70K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON2 holders above 5% have filed on IOVA, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.5% of the class (33,366,587 shares), filed 2026-07-28 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 24.5M | 5.5% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 33.4M | 7.5% | 2026-06-30 |
13F holders
Tracked managers holding IOVA at their latest 13F. JSON5 of the 30 tracked managers held IOVA at their latest 13F, $154.7M in total at quarter-end prices. Two Sigma Investments is the largest at $79.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 19.0M | $79.1M | 0.06% | +5.3M |
| Millennium Management | 2026-06-30 | 8.5M | $35.5M | 0.01% | +4.1M |
| AQR Capital Management | 2026-06-30 | 3.9M | $16.1M | 0.01% | +3.2M |
| Citadel Advisors | 2026-06-30 | 3.6M | $15.1M | 0.00% | -223K |
| D. E. Shaw & Co. | 2026-06-30 | 2.1M | $8.9M | 0.00% | -5.9M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $99.3M, up 65.7% from the same quarter a year earlier, and net loss of $47.3M (-0.11 diluted EPS). In FY 2025 it generated -$302.4M of operating cash flow.
- Cash
- $110.8M
- Equity
- $736.0M
- Total assets
- $915.5M
- Shares outstanding
- 452,971,432
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $99.3M | -$47.3M | -47.6% | -0.11 |
| Q1 2026 | 2026-03-31 | $71.4M | -$79.0M | -110.7% | -0.19 |
| Q4 2025derived | 2025-12-31 | $86.8M | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $67.5M | -$91.3M | -135.3% | -0.25 |
| Q2 2025 | 2025-06-30 | $60.0M | -$111.7M | -186.2% | -0.33 |
| Q1 2025 | 2025-03-31 | $49.3M | -$116.2M | -235.5% | -0.36 |
| Q4 2024derived | 2024-12-31 | $73.7M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $58.6M | -$83.5M | -142.7% | -0.28 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $263.5M | n/a | -$302.4M | $33.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $164.1M | n/a | -$353.0M | $11.1M | n/a | n/a |
| FY 2023 | 2023-12-31 | $1.2M | n/a | -$361.8M | $22.3M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | n/a | -$292.8M | $20.4M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | n/a | -$227.9M | $37.6M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.
What this page is
IOVANCE BIOTHERAPEUTICS, INC. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows IOVANCE BIOTHERAPEUTICS, INC. (IOVA), SEC CIK 1425205, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-11.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1425205Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
Datasets
Frequently Asked Questions
How much of IOVA is sold short?
What is IOVA's daily short volume?
Does IOVA have fails to deliver?
Are IOVA insiders buying or selling?
Who owns more than 5% of IOVA?
What did IOVA report last quarter?
Which funds hold IOVA?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.